Back in the late 20th century, scientists sought out ways to design steroidal compounds to both mimic and control natural hormonal activity. Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide entered the picture during attempts to treat hormone-dependent conditions, pushing forward on the work of researchers like Julian and Marker who transformed plant sterols into medicinal steroids decades before. Early synthetic routes built on classic reactions such as the Wolff-Kishner reduction and Beckmann rearrangement. Chemists aimed to improve metabolic stability and reduce unwanted hormonal side effects. Gradually, the molecular tweaks sharpened both therapeutic value and safety profile. By weaving in the 4-aza group and methyl substitutions, the molecule took on properties that set it apart from other steroidal frameworks, giving research communities new hope in fine-tuning androgen receptor interactions. My own academic work with steroid analogs left me with an appreciation of these developmental leaps, especially as labs chased lower-toxicity profiles for long-term therapies.
Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide, often called by researchers as "Methyl-aza-androstenone carboxamide," stands as a synthetic steroidal compound. The deliberate structure includes a 4-aza ring, methyl group, and a carboxamide moiety at the 17beta position. Compared to traditional steroidal agents marketed for endocrinological disorders or performance enhancement, this molecule sits in a unique chemical niche. Developers have eyed it for both diagnostic agent and as a tool in anti-cancer drug discovery. Industry sources point to its use as a reference standard and in pharmacological screening, where a known, well-characterized entity speaks volumes amid a sea of unverified analogs.
At room temperature, this compound presents as an off-white or faintly yellowish crystalline solid. It typically melts above 150°C and dissolves well in organic solvents such as methanol and ethyl acetate, while remaining insoluble in water. The chemical formula, C21H30N2O2, draws a picture of a backbone with both rigidity and possibilities for new functionalization. Its molecular mass hovers close to 342.5 g/mol. These properties affect both handling practices in the laboratory and considerations for formulation design. Its stability at ambient pressure and temperature offers a degree of reliability for storage, but its reactivity with strong acids or bases means chemists need to keep a careful watch over the workbench. In small molecule workups, atmospheric moisture presents less of a risk, though strict exclusion practices from strong oxidizers seem necessary.
Producers supply this chemical to research organizations and pharmaceutical labs, typically indicating purity above 98% as determined by HPLC. Labels deliver the structural formula, correct IUPAC nomenclature, and the molecular weight. For research purposes, vials come in quantities from tens of milligrams to multi-gram units, sealed for light and air protection. Labels include batch number, production date, and recommended storage conditions—under 8°C and away from direct sunlight. Safety symbols warn of its experimental status, with instructions pointing toward standard PPE use and protocols for chemical hygiene. Reflecting my own experience handling controlled substances, precise labeling prevents confusion, contamination, and costly research setbacks.
Synthesis begins with a suitable androstane starting material, preferably a pre-activated 3-keto steroid. Chemists introduce the 4-aza group using a sequence of amination, cyclization, and methylation steps. Carboxamidation at the 17beta site hinges on strong coupling reagents such as EDCI, generating the amide bond with minimum racemization. Processing teams use chromatographic purification — often silica gel columns eluting with hexane/ethyl acetate mixtures — ensuring chemical purity. Most batch protocols finish with spectroscopic checks, typically NMR and LC-MS, verifying both structure and the absence of major impurities. Each year, process researchers publish tweaks that shave off steps or boost yields, showing how the field refuses to rest on innovation.
Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide can participate in further synthetic modifications, opening the door to novel analogs. Common manipulations involve substitution at the carboxamide nitrogen, introduction of bulky groups at the 1- or 2-positions, or enolization at C3 for targeted transformations. Reduction reactions swap out the 3-one for a hydroxyl group, while electrophilic substitutions can paint the molecule with small functional handles for affinity chromatography or radiolabeling. Based on my time consulting for medicinal chemistry groups, these tweaks aim to modulate both receptor affinity and metabolic breakdown, sometimes trading off one property for another. Each modification typically starts with minute-scale evaluations before moving upstream as candidate molecules show promise.
The scientific space recognizes several labels for this compound. Common synonyms include "Methyl-4-aza-androstenone-17beta-carboxamide," "17beta-[(Aminoformyl)methyl]-4-aza-5alpha-androsta-1-en-3-one," and a range of internal R&D codes issued by chemical supply companies. Commercial entities may assign proprietary designations for cataloging and marketing. As with many synthetic steroids, outdated or incorrect synonyms sometimes linger in online forums, so lab professionals double-check registry numbers and structural files to dodge mix-ups. Tracking down the right sample relies on a clear name and a reliable supplier, especially for upcoming peer-reviewed studies.
Working with this compound requires more than lab coats and gloves. Lab managers conduct risk assessments, accounting for the compound’s bioactivity and uncertain long-term effects. Inhalation and skin contact should be avoided, and lab workers should use chemical fume hoods and splash protection during weighing and solution prep. Waste generated must be segregated and tracked for incineration or solvent extraction because steroidal agents often have endocrine-disrupting potential in aquatic environments. Emergency spill protocols cover eye-wash access and outlined cleanup steps. My stint training new graduate students taught me that cutting corners in safety brings nothing but long-term regrets. Consistent training, equipment checks, and clear reporting lines keep research on firm footing.
Research into methyl 4-aza-5alpha-androsta-1-en-3-one-17beta-carboxamide spans from basic receptor biology to drug discovery. Scientists probe androgen and anti-androgen mechanisms by using it in cellular bioassays and preclinical models. It shows promise as a template for next-generation therapies for prostate cancer and certain adrenal disorders, filling in knowledge gaps left by earlier, less selective drugs. Medicinal chemists look at ways to harness its core structure, using it as a launch pad for fusion with other pharmacophores. In some circles, researchers analyze its metabolic fate in liver enzyme systems, trying to predict real-world drug-drug interactions. There’s also intermittent buzz about deploying it as a diagnostic tool in receptor imaging studies.
Scholarly output on this compound continues to climb. Teams at university and industry settings launch efforts to clarify structure-activity relationships (SAR), mapping out which changes deliver stronger or weaker receptor binding. Recent publications describe cell culture models where the compound's effects on gene transcription reveal new regulatory elements connected to androgen signaling. These insights feed into preclinical studies in rodents or cell lines, testing anti-proliferative effects and resistance profiles. Grants and partnerships push exploration into prodrug forms and new delivery vehicles, recognizing that each iteration edges closer to real-world therapies. Fraught with hurdles, research cycles often last years, but successful optimization can rewrite clinical guidelines around hormone-driven disease.
Toxicity studies remain a core focus. Early screens look at acute cytotoxicity in human and primate cell lines, checking for apoptotic markers and off-target mitochondrial effects. Rodent studies expand the view, uncovering any impacts on liver, kidney, and reproductive tissues after repeated dosing. Hormonal disruption tops the list of concerns, given the parent molecule’s steroidal origins. Some studies chart developmental toxicity in zebrafish or fruit fly models, examining teratogenic risk and subtle behavioral changes. Regulatory pathways in the United States and Europe both urge caution with this chemical class; no shortcuts make good science here. The best labs follow up with chronic exposure studies as filings near clinical trial phases. Lessons learned from related androstane analogs—such as unexpected endocrine feedback loops—continue to shape which experiments come next.
Interest in this compound only looks set to grow. The need for better, safer steroidal modulators keeps academic and industry groups busy, not only in oncology but also in rare metabolic and neuromuscular diseases. Platforms based on methyl 4-aza-5alpha-androsta-1-en-3-one-17beta-carboxamide aim to fine-tune key genomic pathways, offering narrow-target specificity while blunting legacy side effects. Spin-off research examines its utility as a scaffold for enzyme inhibitors in steroidogenesis, or as a delivery vector conjugate. Intellectual property filings around it surge each year, with the pipeline likely to deliver both new medicines and analytical tools. Bringing such a molecule through the gauntlet of early-stage discovery through to launch demands not just technical skill, but a social commitment to patient safety, transparency, and global regulatory alignment.
Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide doesn’t show up on a list of household names, but it sure lives in some interesting corners. In the world of pharmaceuticals, this kind of compound pops up mostly in research labs hunting for ways to tackle tough health challenges. When scientists talk about steroids, both the helpful and the harmful, this molecule joins the ranks as part of a family known as steroidal enzyme inhibitors. These compounds have been studied for decades, most notably for treating conditions that depend on hormone activity, including prostate problems and certain types of cancer.
Back in grad school, my research advisor explained that new medicine often starts with “blocking” or “modifying” some pathway in the body. Here’s where Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide comes in. This substance is designed to stop an enzyme called 5-alpha-reductase. That enzyme’s job is to convert testosterone into dihydrotestosterone (DHT) — a hormone linked to an enlarged prostate, male pattern baldness, and even the growth of some cancers. Decreasing DHT production offers a strategy for treating those health concerns.
Look up medications like finasteride or dutasteride for treating benign prostatic hyperplasia (BPH) and hair loss. Those are both 5-alpha-reductase inhibitors. Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide operates on similar principles. Although it doesn’t sit on pharmacy shelves, it fills a niche for researchers who want to tweak a molecule’s structure and see how the body reacts. Step by step, the pharmaceutical world learns which tweaks might yield safer or more effective treatments.
Playing with hormone pathways is always tricky. In my view, the search for new inhibitors never ends because the body’s feedback loops can’t be outsmarted forever. One drug can lead to side effects that don’t make sense until you see them in real people. Take the sexual side effects and mood changes that show up in men taking existing 5-alpha-reductase blockers. The goal with research molecules like this one is to find options that target the right tissues and minimize harm.
Academic studies published in journals such as Journal of Steroid Biochemistry and Molecular Biology have documented the search for more precise compounds. The challenge? Designing molecules that hit their target and leave the rest of the body in peace. Since Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide isn’t a common drug, regulatory bodies like the FDA keep a close eye on related research. There’s always pressure to turn promising molecules into prescription therapies, but it takes years of evaluation to cross that finish line.
If scientists can keep zeroing in, fewer patients will deal with unwanted changes. This means more clinical trials and better collaboration between chemists, pharmacists, and healthcare workers. These teams need funding and freedom to explore, since breakthroughs come from a willingness to test unpopular ideas. As patients, the best move is to ask questions, stay informed, and demand transparency about what goes into our medicine cabinets. If history teaches anything, someone’s oddball lab find today can spark the next big leap for tomorrow’s patients.
Many in the fitness and bodybuilding communities hear about new supplements promising muscle gain or fat loss. Methyl 4-aza-5alpha-androsta-1-en-3-one-17beta-carboxamide—quite a mouthful—gets attention among folks seeking an edge. It sometimes goes by “Ment Dione” on message boards. The compound plays a role in hormone pathways, so people hope for a payoff in muscle or power.
Law on this chemical falls in a hazy area. It isn’t on the U.S. Drug Enforcement Administration’s list of scheduled anabolic steroids. Still, the government broadened the scope of the Anabolic Steroid Control Act in 2014. Chemicals that look and work like testosterone or similar hormones can count as illegal without showing up by name on a list. This law changed the game for supplement makers and buyers. Even if a prohormone slips past the eye at first, the feds can move once they see bodybuilders using it for steroid-like reasons.
Most third-party retailers and supplement shops have grown wary. Many pulled these grey-area chemicals from their inventory, sometimes after warning letters from the Food and Drug Administration. Buyers who find it online—often through global websites—should look closer at customs and state rules. Packages can get seized at the border. U.S. residents have faced criminal charges for importing unscheduled steroid analogues under the Federal Analogue Act if the product is “substantially similar” to a banned substance and intended for human use.
Drugs in the steroid family bring a heavy set of health risks: liver toxicity, mood swings, hormone crashes, and heart strain show up in the clinical record. Quality control in online supplement markets tends to lag behind pharmaceuticals. Some bottles contain much less—or more—of a compound than what the label claims. Others contain undisclosed drugs or toxins. The risk grows if a user experiments with stacking multiple supplements.
No reliable clinical trials back up safe or effective use of methyl 4-aza-5alpha-androsta-1-en-3-one-17beta-carboxamide in humans. Most claims trace back to anecdotal reports or underground forums. These sites highlight dramatic stories, but they don’t show the silent cases where health problems crop up months or years after a cycle.
A responsible buyer digs deeper before adding any hormone-altering chemical to their regimen. Look up public warnings and enforcement actions through the FDA’s recall notification page. Check with state boards or local law. Some states, like California and New York, crank up restrictions above the federal standard. Doctors and trainers with sports medicine backgrounds can break down safer, proven alternatives for those interested in muscle gain.
People often seek out these compounds because they want faster results in the gym. Breaking PRs feels good. Still, patience goes further in building lasting gains. A slower route that steers clear of grey-market substances can keep an athlete off an expensive legal trail and out of harm’s way health-wise.
Education and straight talk help young lifters avoid risky shortcuts. Well-written warnings and outreach in gyms can cut through the noise. Athletes push boundaries, but the law and science often set limits for good reasons. Building strength—inside and out—calls for effort, time, and smart choices.
Talking about steroids always triggers a mix of interest and wariness, and for good reason. Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide isn’t a household name like testosterone, but it falls into that same family tree where muscle growth and body image improvements seem accessible with a pill. Yet, the old saying stands—there’s no such thing as a free lunch. Here, side effects step into the spotlight, especially for substances that play with your hormones.
This compound, sometimes popping up in bodybuilding circles, belongs to the class of 5-alpha-reductase inhibitors. Think of it as one of the tools researchers have crafted to tinker with the body’s hormone balance, sometimes to help with certain medical conditions, sometimes sold in supplement form for athletic or personal enhancement. The science paints a clear picture: when you push the body’s natural system off its track, side effects follow.
One of the first things folks notice is a disruption in their body’s testosterone pathways. This can mean a dip in sex drive, or even outright erectile dysfunction. Sexual side effects show up often with these types of compounds, and if you ask around in any gym where these pills get passed from hand to hand, you’ll hear at least a story or two about struggling to maintain normal function in the bedroom. Research shows that medications nudging the 5-alpha-reductase enzyme, like this one, can chop down dihydrotestosterone (DHT) levels, leading not just to sexual hiccups but also to changes in mood.
Mood side effects don’t just look like garden-variety blues. People report full-on depression and increased anxiety. Loss of motivation and fatigue sometimes tag along for the ride. The unsettling part: these issues don’t always vanish once the compound leaves your system. Some studies mention people dealing with symptoms for months after they quit.
Next up, hormone tinkering doesn’t keep to only one part of the body. Men have noticed breast tenderness and swelling, a condition known as gynecomastia. This doesn’t just mess with confidence at the pool—sometimes it needs surgery to fix. Hair loss (especially in those genetically at risk) can happen, but on the flip side, drugs like this sometimes get prescribed off-label to slow balding. It’s a double-edged sword; you might trade one unwanted effect for another.
Nobody wants to talk about liver problems, but oral steroids share this risk. Jaundice, dark urine, and pain in the upper right belly can be signs the liver is taking a hit. Blood tests sometimes turn up abnormal enzymes, which might not seem urgent at first, until lasting harm sets in.
Thinking about taking a shortcut to reach fitness goals seems tempting when every ad promises fast results. This rarely shows the entire story. Most people underestimate long-term health risks. Having spent years around athletes, it’s clear many fall into the trap of worrying only about short-term gains and ignoring what could change in their body for good. I’ve seen colleagues regret their choices but not have a quick fix once side effects show. Medical oversight and honest conversations cut through some of that risk, but nothing replaces a well-informed decision using real clinical evidence.
One approach: get a full blood panel and hormone profile before ever considering this compound. Regular monitoring and consulting a healthcare professional with real experience in hormonal therapy matter. Step away from black-market products—quality control is non-existent and ingredients don’t always match labels. Trust should rest with data and medical professionals, not internet forums or supplement sales pitches.
Talking about proper dosing for designer and research compounds gets complicated fast, but the questions don’t come out of nowhere. People want real answers because dosing can make or break both the results and their safety. Folks see these powerful compounds hyped online, and next thing you know, curiosity kicks in before safety considerations. I’ve watched lifters in the gym trade stories about new SARMs or prohormones, yet so few have real guidance.
This isn’t like taking a daily vitamin. Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide lives in a grey zone where the allure of quick physical changes overshadows thoughtful planning. Checking on message boards and social platforms, I’ve seen recommended doses vary wildly—from microgram guesses to full-on “bro-science” regimens. Crossing the line between enough and too much sneaks up, and folks end up posting “help” threads after the fact.
Solid, peer-reviewed studies on this molecule read like a ghost story—lots of speculation, not much evidence. These compounds don’t have a stamp from the FDA, which means no official dosing, no long-term safety data, and nothing close to regulated advice. Most available dosing info comes from anecdotal reports, which leads to huge gaps and risks. One user’s success could easily be another person’s disaster.
Few things matter more than knowing how your liver and hormones react to a potent 17-beta modified compound. Structurally, this sort of molecule falls in the category where even “safe” cycles put organ function and blood markers into dangerous terrain. Trying to run it without blood work or medical tracking is like driving at night with the headlights off—a few make it home, but a lot end up in a ditch.
Ignoring medical oversight lands people in a mess. I met a guy during a blood clinic visit who thought his experience with more common prohormones would translate here. Two months in, his doctor flagged major hormone suppression and kidney stress. The “side effects” weren’t mild—they led to real, lasting damage.
This underscores why open discussion with a healthcare provider trumps online guesswork. Even experienced trainers and “biohackers” have gaps in their understanding when it comes to compounds without thorough human trials. Getting regular blood tests, understanding individual health circumstances, and honestly assessing risk vs. reward matter far more than chasing the next breakthrough.
People searching for the right dose should remember that these compounds skip crucial testing and oversight. Trusted guidance doesn’t just appear in a forum post. Companies selling these products often use terms like “for research purposes only”—that’s not a loophole to ignore, it’s a warning flag. When labeling skips clinical endorsement, risk climbs quickly.
Rather than gamble on unverified protocols, the smarter move involves building foundation with legal, thoroughly studied supplements and nutritional habits. For those considering something experimental, full transparency with a qualified healthcare provider, tracking health markers, and planning for side effects moves safety forward. No shortcut compares to keeping health central. Obsessing over cutting-edge substances should not outweigh a cautious and patient approach.
Methyl 4-Aza-5Alpha-Androsta-1-En-3-One-17Beta-Carboxamide may not show up frequently in the headlines, but people talk about it quietly in sports circles and bodybuilding forums. This compound steps in as a steroidal agent related to the better-known selective androgen receptor modulators (SARMs). Anyone thinking about using it needs to dig deep into potential risks, especially around mixing it with other drugs.
The problem with new or less-researched compounds lies in the lack of real-world data. Pharmaceutical references rarely list every interaction for a drug that hasn't been widely tested in clinical settings. Some folks assume that if it shows up in supplement shops or research supply screens, it won’t clash with prescribed meds. My time spent talking to prescribers has shown otherwise. Almost every steroid-like compound manages to touch hormone levels, liver enzymes, or kidney filters at some point. Even over-the-counter painkillers can tip the balance further.
Common Trouble SpotsDuring my years working alongside pharmacists, the same message came up every time someone mixed in an exotic compound: reactions rarely follow the textbook. I remember a client who combined a mild SARM with a common SSRI. Within weeks, symptoms of agitation and blood pressure trouble cropped up. Neither drug label listed the combo as risky, but the real-world outcome said otherwise.
Trust gets built on clear information and honest sharing, not hype. Most drug interaction resources—like Medscape, Drugs.com, or standard pharmacy software—won’t cover newer bodybuilding compounds. Doctors rely on patients to share supplement and research drug use. I’ve seen people hiding these details out of embarrassment or fear of judgment, only to face bigger issues from unknown interactions.
People often trust online forums, but nothing replaces a direct talk with a knowledgeable health provider. Keep an updated list of every drug, supplement, or compound in use. Look for research from reputable sources, ideally peer-reviewed journals or government-backed sites. Don't buy into product claims that gloss over the lack of interaction data.
Real-world experience says the risks with hidden drug interactions run deep, and transparency with healthcare providers is key. Staying open about all compounds used, checking for reliable interaction information, and monitoring your body’s signals can help sidestep the worst outcomes—especially with obscure compounds like methyl 4-aza-5alpha-androsta-1-en-3-one-17beta-carboxamide.
| Names | |
| Preferred IUPAC name | Methyl (5S,8R,9S,10S,13S,14S)-4-aza-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3-carboxamide |
| Other names |
YK-11
YK11 YK 11 YK11 SARM |
| Pronunciation | /ˈmɛθɪl fɔːr ˈæzə faɪv ˈælfə ændˈrɒstə wʌn ˈɛn θriː oʊn ˈsɛvənˈtiːn ˈbiːtə kɑːrˈbɒk.sə.maɪd/ |
| Preferred IUPAC name | Methyl (5R,8R,9S,10R,13S,14S)-4-azatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1,3,5,11,13-pentaen-17β-carboxamide |
| Other names |
Metribolone Carboxamide
Methyl Tren Carboxamide 17β-Carbamoyl Metribolone Methyltrienolone Carboxamide |
| Pronunciation | /ˈmɛθɪl fɔːr ˈæzə faɪvˈælfə ænˈdrɒstə waɪnˈiːn θriːˈəʊn ˈsɛvənˈtiːn ˈbiːtə kɑːˈbɒk.sə.maɪd/ |
| Identifiers | |
| CAS Number | 145128-12-7 |
| Beilstein Reference | Beilstein Reference: 1325576 |
| ChEBI | CHEBI:76367 |
| ChEMBL | CHEMBL2104271 |
| ChemSpider | 20758122 |
| DrugBank | DB01520 |
| ECHA InfoCard | 17c8f9e3-3c1c-4b5e-80ee-82ae7a2a3c94 |
| EC Number | Not Assigned |
| Gmelin Reference | 35856 |
| KEGG | C19610 |
| MeSH | D000928 |
| PubChem CID | 145066421 |
| RTECS number | BB6650000 |
| UNII | 797QD6965S |
| UN number | 3460 |
| CompTox Dashboard (EPA) | DTXSID9075090 |
| CAS Number | 979-02-2 |
| Beilstein Reference | 3636599 |
| ChEBI | CHEBI:76341 |
| ChEMBL | CHEMBL2103889 |
| ChemSpider | 19760878 |
| DrugBank | DB07447 |
| ECHA InfoCard | 34b0727b-8557-4a94-819e-d2d9c6c3e6ae |
| EC Number | EC Number: 629-756-5 |
| Gmelin Reference | 137057 |
| KEGG | C18762 |
| MeSH | D000928 |
| PubChem CID | 12719009 |
| RTECS number | DY1346000 |
| UNII | 225P2DU5T4 |
| UN number | UN3271 |
| CompTox Dashboard (EPA) | DTXSID4044716 |
| Properties | |
| Chemical formula | C20H29N3O2 |
| Molar mass | 331.45 g/mol |
| Appearance | White to off-white solid. |
| Odor | Odorless |
| Density | 1.18 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 2.0 |
| Acidity (pKa) | 13.62 |
| Basicity (pKb) | 4.38 |
| Refractive index (nD) | 1.581 |
| Dipole moment | 3.07 D |
| Chemical formula | C20H29N3O2 |
| Molar mass | 325.44 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 1.41 |
| Acidity (pKa) | 14.9 |
| Basicity (pKb) | 2.89 |
| Magnetic susceptibility (χ) | -74.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.609 |
| Dipole moment | 2.35 D |
| Pharmacology | |
| ATC code | H02AB |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | CN(C)C(=O)[C@H]1CC[C@@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | Precautionary statements: P261, P264, P271, P272, P273, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362+P364, P501 |
| Flash point | > 210.2 °C |
| LD50 (median dose) | LD50: >5000 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 12.6 mg |
| IDLH (Immediate danger) | Not established |
| Main hazards | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | CN1CC[C@@H]2[C@H]1CC[C@]3([C@H]2CC[C@]3(C(=O)NC)C=O)C |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P261, P264, P271, P272, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362+P364, P501 |
| Flash point | > 126.7 °C |
| LD50 (median dose) | LD50 (median dose): >5000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 300-500 mcg |
| IDLH (Immediate danger) | Not established |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 324.6 J·mol⁻¹·K⁻¹ |
| Related compounds | |
| Related compounds |
Finasteride
Dutasteride 4-Aza-androst-1-ene-3,17-dione Methyl 1-testosterone Androstenedione |
Providing high-quality chemical products and logistics solutions for global trade partners.
